Secondary analysis of AHOD1331 in 340 children and young adults with stage IV classic Hodgkin lymphoma: Bv-AVEPC improved PFS vs ABVE-PC overall (HR 0.53, 90% CI 0.33-0.85) and with lung-only or bone-only disease, but not with bone marrow-only involvement.
Secondary analysisn = 340
Casey et al. Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial